For Healthcare Professionals

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs


About the study

The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs. The long term extension period will provide additional long-term efficacy and safety information.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. Diagnosed to have psoriatic arthritis (PsA) of at least 3 months duration at screening
  2. Meets the Classification Criteria for Psoriatic Arthritis at Screening
  3. Active plaque psoriatic skin lesion(s) or documented medical history of plaque psoriasis (PsO) at screening
  4. Active arthritis as shown by ≥ 3 swollen joints and ≥ 3 tender joints at Screening and day 1
  5. Participant has high sensitivity C-reactive protein (hsCRP) ≥ 3 mg/L at Screening
  6. ≥ 1 PsA-related hand and/or foot joint erosion on X-ray during Screening Period that is confirmed by central reading
  7. Must have completed the week 52 treatment for the optional open-label long-term extension period


Exclusion Criteria:

  1. Nonplaque psoriasis at screening or day 1
  2. Other autoimmune condition such as systemic lupus erythematous, mixed connective tissue disease, multiple sclerosis, or vasculitis
  3. History of or current inflammatory joint disease other than PsA (e.g., gout, reactive arthritis, rheumatoid arthritis, ankylosing spondylitis, Lyme disease)
  4. Active fibromyalgia
  5. Received an approved or investigational biologic therapy for the treatment of PsA or PsO

Other protocol-defined inclusion/exclusion criteria apply

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Psoriatic Arthritis

Age (in years)



Phase 3

Participants needed


Est. Completion Date

May 12, 2027

Treatment type



Bristol-Myers Squibb identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.